R&D
Innovating in China’s pharma market
April 12, 2012Research and Development AstraZeneca, China, R&D, Steve Yang, emerging markets
The challenges that China and the wider Asia region face in healthcare represent big opportunities for multinational pharma companies. Cases of …
The brain drain
April 5, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, R&D, brain drain, research and development
Concerns about the growing number of companies disinvesting from neuroscience research have been growing in recent years, and the latest …
Early-stage research gains another funding boost
March 23, 2012Research and Development, Sales and Marketing GSK, Index Ventures, Janssen, R&D
GlaxoSmithKline and Janssen are among the key investors in a venture capital fund aimed solely at identifying promising pharma start-ups. …
AstraZeneca pulls depression drug, takes $50m hit
March 20, 2012Research and Development, Sales and Marketing AstraZeneca, R&D, depression, failure, pipeline
AstraZeneca and partner Targacept will not file their depression drug TC-5214 for regulatory review. The decision comes after disappointing Phase …
AstraZeneca touting for business at partnering conference
March 19, 2012Research and Development, Sales and Marketing AstraZeneca, Bio-Europe, R&D, partnering
AstraZeneca is marketing itself as a key partner for drug development deals, ahead of a European partnering conference. The Bio-Europe …
Science minister opens new Pfizer facility in Havant
March 13, 2012Manufacturing and Production Havant, Pfizer, R&D, Tucker, Willetts
Science minister David Willetts has opened Pfizer’s new state-of-the-art cold storage facility at its site in Havant. The new £7 …
GSK expands apprenticeship programme
March 13, 2012Manufacturing and Production, Research and Development GSK, Hayes, R&D, manufacturing
GlaxoSmithKline has expanded its apprenticeship programme with the creation of positions spanning manufacturing, IT, and R&D. The multi-disciplinary scheme is …
Academic alliances to speed Lilly’s R&D
March 1, 2012Research and Development, Sales and Marketing R&D, academia, break through drugs, collaboration, lilly
Lilly has unveiled a range of collaborations with academic researchers which it says will help it discover and develop more …
Biogen to pay $563 million for Stromedix
February 15, 2012Research and Development, Sales and Marketing Bioden Idec, R&D, STX-100, Stromedix
Biogen Idec will acquire the specialist immunology firm Stromedix for around $500 million. Biogen currently focuses on the development of …
GSK posts strong underlying sales growth
February 8, 2012Research and Development, Sales and Marketing Avodart, GSK, R&D, Seretide, Witty, rotarix
GlaxoSmithKline has posted strong underlying growth for 2011, but warns of a tough year ahead. The UK firm saw 4% …
AstraZeneca to cut 7,300 jobs as growth stalls
February 2, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing AZ, AstraZeneca, David Brennan, R&D
AstraZeneca will make 7,300 cuts to its sales and R&D staff by 2014, but the company has not yet said …
Amylin to pay up to $1.6 billion to sever ties with Lilly
November 8, 2011Research and Development, Sales and Marketing Amylin, Bydureon, Byetta, R&D, lilly
Amylin will pay up to $1.6 billion to end its diabetes pact with Lilly after a difficult year for the …
UK pharma downbeat on its future – survey
November 8, 2011Research and Development ABPI, R&D, VBP, rsa
The impacts of NHS reform and the increasingly high cost of R&D is causing pharma to doubt its future in …
Ex-Pfizer R&D head Dr David Roblin joins Destiny Pharma
November 7, 2011Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Destiny Pharma, Pfizer, R&D
Anti-microbial drug developers Destiny Pharma have appointed Dr David Roblin as its new medical director. Dr Roblin was formerly head …
Lundbeck appoints two new R&D vice presidents
November 1, 2011Research and Development Lundbeck, R&D
Lundbeck has appointed Jens Peter Balling and Iman Barilero as vice presidents of its research and development organisation. The new …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
